Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients

Clinical and Experimental Medicine

Volumn 15, Issue 3, 2015, Pages 415-420

  Leal, Mariana Ferreira ^a   Calcagno, Danielle Queiroz ^a,c   Chung, Janete ^a   de Freitas, Vanessa Morais ^b   Demachki, Samia ^c   Assumpção, Paulo Pimentel ^c   Chammas, Roger ^b,d   Burbano, Rommel Rodríguez ^c   Smith, Marília Cardoso ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^d Instituto do Cancer do Estado de Sao Paulo   (Brazil)

Author keywords

Annexin 2; Galectin 3; Gastric cancer; Membrane proteins; Proteomic

Indexed keywords

GALECTIN 3; LIPOCORTIN 2;

ADULT; CELL MEMBRANE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CYTOPLASM; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOFLUORESCENCE; IN VITRO STUDY; LETTER; MALE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; AGED; BRAZIL; CELL PROLIFERATION; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; ANNEXIN A2; BLOTTING, WESTERN; BRAZIL; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CYTOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GALECTIN 3; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 84938414934     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-014-0299-0     Document Type: Letter

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
2. Shah MA, Ajani JA. Gastric cancer—an enigmatic and heterogeneous disease. JAMA. 2010;303:1753–4. doi:10.1001/jama.2010.553.
3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.
4. Adam PJ, Boyd R, Tyson KL, et al. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem. 2003;278:6482–9. doi:10.1074/jbc.M210184200.
5. Leal MF, Chung J, Calcagno DQ, Assumpcao PP, et al. Differential proteomic analysis of noncardia gastric cancer from individuals of northern Brazil. PLoS One. 2012;7:e42255. doi:10.1371/journal.pone.0042255PONE-D-11-08927.
6. Batista dos Santos SE, Rodrigues JD, Ribeiro-dos-Santos AK, Zago MA. Differential contribution of indigenous men and women to the formation of an urban population in the Amazon region as revealed by mtDNA and Y-DNA. Am J Phys Anthropol. 1999;109:175–80. doi:10.1002/(SICI)1096-8644(199906)109:2<175::AID-AJPA3>3.0.CO;2-%23.
7. Leal MF, Martins do Nascimento JL, da Silva CE, et al. Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. Cancer Genet Cytogenet. 2009;195:85–91. doi:10.1016/j.cancergencyto.2009.04.020.
8. Leal MF, Calcagno DQ, Costa JFFB, et al. MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors. J Biomed Biotechnol. 2011;. doi:10.1155/2011/631268.
9. Calcagno DQ, Freitas VM, Leal MF, et al. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol. 2013;13:141. doi:10.1186/1471-230X-13-141.
10. da Costa Jde F, Leal MF, Silva TC, et al. Experimental gastric carcinogenesis in Cebus apella nonhuman primates. PLoS One. 2011;6:e21988. doi:10.1371/journal.pone.0021988PONE-D-11-03343.
11. Guo T, Fan L, Ng WH, et al. Multidimensional identification of tissue biomarkers of gastric cancer. J Proteome Res. 2012;. doi:10.1021/pr300212g.
12. Hofmann A, Gerrits B, Schmidt A, et al. Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. Blood. 2010;116:e26–34. doi:10.1182/blood-2010-02-271270.
13. Ponten F, Jirstrom K, Uhlen M. The human protein atlas—a tool for pathology. J Pathol. 2008;216:387–93. doi:10.1002/path.2440.
14. Leal MF, Mazzotti TK, Calcagno DQ, et al. Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications. BMC Gastroenterol. 2014;14:9. doi:10.1186/1471-230X-14-9.
15. Leal MF, Calcagno DQ, Demachki S, et al. Clinical implication of 14-3-3 epsilon expression in gastric cancer. World J Gastroenterol. 2012;18:1531–7.
16. Emoto K, Sawada H, Yamada Y, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21:1339–45.
17. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82:331–71. doi:10.1152/physrev.00030.2001.
18. Filipenko NR, Waisman DM. The C terminus of annexin II mediates binding to F-actin. J Biol Chem. 2001;276:5310–5. doi:10.1074/jbc.M009710200.
19. Hansen MD, Ehrlich JS, Nelson WJ. Molecular mechanism for orienting membrane and actin dynamics to nascent cell–cell contacts in epithelial cells. J Biol Chem. 2002;277:45371–6. doi:10.1074/jbc.M207747200.
20. Babbin BA, Parkos CA, Mandell KJ, et al. Annexin 2 regulates intestinal epithelial cell spreading and wound closure through Rho-related signaling. Am J Pathol. 2007;170:951–66. doi:10.2353/ajpath.2007.060647.
21. Dong WG, Yu QF, Xu Y, Fan LF. Li-cadherin is inversely correlated with galectin-3 expression in gastric cancer. Dig Dis Sci. 2008;53:1811–7. doi:10.1007/s10620-007-0080-2.
22. Miyazaki J, Hokari R, Kato S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002;9:1307–12.
23. Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol. 2000;21:258–66.
24. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006;26:1369–76.
25. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 1999;27:362–7.
26. Pacis RA, Pilat MJ, Pienta KJ, et al. Decreased galectin-3 expression in prostate cancer. Prostate. 2000;44:118–23. doi:10.1002/1097-0045(20000701)44:2<118:AID-PROS4>3.0.CO;2-U.
27. van den Brule FA, Berchuck A, Bast RC, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 1994;30A:1096–9.
28. Lotz MM, Andrews CW Jr, Korzelius CA, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA. 1993;90:3466–70.
29. Choufani G, Nagy N, Saussez S, et al. The levels of expression of galectin-1, galectin-3, and the Thomsen–Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 1999;86:2353–63.
30. Castronovo V, Van Den Brule FA, Jackers P, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996;179:43–8. doi:10.1002/(SICI)1096-9896(199605)179:1<43:AID-PATH541>3.0.CO;2-N.
31. de Oliveira JT, de Matos AJ, Gomes J, et al. Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. Glycobiology. 2010;20:1341–52. doi:10.1093/glycob/cwq103.